Narrative review: precision medicine applications in neuroblastoma—current status and future prospects

Jiao Zhou,Hongmei Du,Weisong Cai

DOI: https://doi.org/10.21037/tp-23-557

2024-01-28

Translational Pediatrics

Abstract:Keywords: Neuroblastoma (NB); precision medicine; targeted therapy; molecular biomarker

pediatrics

What problem does this paper attempt to address?

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Hui Yan,Bo Zhai,Fang Yang,Zhenliang Chen,Qiang Zhou,Ana Cláudia Paiva-Santos,Ziqiao Yuan,Yang Zhou

DOI: https://doi.org/10.3389/fphar.2022.908713

IF: 5.6

2022-06-02

Frontiers in Pharmacology

Abstract:Neuroblastoma (NB), as the most common extracranial solid tumor in childhood, is one of the critical culprits affecting children’s health. Given the heterogeneity and invisibility of NB tumors, the existing diagnostic and therapeutic approaches are inadequate and ineffective in early screening and prognostic improvement. With the rapid innovation and development of nanotechnology, nanomedicines have attracted widespread attention in the field of oncology research for their excellent physiological and chemical properties. In this review, we first explored the current common obstacles in the diagnosis and treatment of NB. Then we comprehensively summarized the advancements in nanotechnology-based multimodal synergistic diagnosis and treatment of NB and elucidate the underlying mechanisms. In addition, a discussion of the pending challenges in biocompatibility and toxicity of nanomedicine was conducted. Finally, we described the development and application status of nanomaterials against some of the recognized targets in the field of NB research, and pointed out prospects for nanomedicine-based precision diagnosis and therapy of NB.

pharmacology & pharmacy
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Min Zheng,Ankush Kumar,Vishakha Sharma,Tapan Behl,Aayush Sehgal,Pranay Wal,Nirmala Vikram Shinde,Bhosale Sachin Kawaduji,Anupriya Kapoor,Khalid Anwer,Monica Gulati,Bairong Shen,Rajeev K. Singla,Simona Gabriela Bungau,Md. Khalid Anwer

DOI: https://doi.org/10.3389/fcell.2024.1353860

IF: 5.5

2024-03-28

Frontiers in Cell and Developmental Biology

Abstract:Neuroblastoma (NB) is the most frequent solid tumor in pediatric cases, contributing to around 15% of childhood cancer-related deaths. The wide-ranging genetic, morphological, and clinical diversity within NB complicates the success of current treatment methods. Acquiring an in-depth understanding of genetic alterations implicated in the development of NB is essential for creating safer and more efficient therapies for this severe condition. Several molecular signatures are being studied as potential targets for developing new treatments for NB patients. In this article, we have examined the molecular factors and genetic irregularities, including those within insulin gene enhancer binding protein 1 (ISL1), dihydropyrimidinase-like 3 (DPYSL3), receptor tyrosine kinase-like orphan receptor 1 (ROR1) and murine double minute 2-tumor protein 53 (MDM2-P53) that play an essential role in the development of NB. A thorough summary of the molecular targeted treatments currently being studied in pre-clinical and clinical trials has been described. Recent studies of immunotherapeutic agents used in NB are also studied in this article. Moreover, we explore potential future directions to discover new targets and treatments to enhance existing therapies and ultimately improve treatment outcomes and survival rates for NB patients.

cell biology,developmental biology
Precision Medicine in Pediatric Neurooncology: A Review

Aaron Y. Mochizuki,Isaura M. Frost,Melina B. Mastrodimos,Ashley S. Plant,Anthony C. Wang,Theodore B. Moore,Robert M. Prins,Paul S. Weiss,Steven J. Jonas

DOI: https://doi.org/10.1021/acschemneuro.7b00388

2017-12-27

ACS Chemical Neuroscience

Abstract:Central nervous system tumors are the leading cause of cancer related death in children. Despite much progress in the field of pediatric neurooncology, modern combination treatment regimens often result in significant late effects, such as neurocognitive deficits, endocrine dysfunction, secondary malignancies, and a host of other chronic health problems. Precision medicine strategies applied to pediatric neurooncology target specific characteristics of individual patients' tumors to achieve maximal killing of neoplastic cells while minimizing unwanted adverse effects. Here, we review emerging trends and the current literature that have guided the development of new molecularly based classification schemas, promising diagnostic techniques, targeted therapies, and delivery platforms for the treatment of pediatric central nervous system tumors.

biochemistry & molecular biology,chemistry, medicinal,neurosciences
Recent advances in molecular genetic characterization of high-risk neuroblastoma

鲁冬芳,陈希,舒强

DOI: https://doi.org/10.3760/cma.j.cn421158-20190801-00472

2021-01-01

Abstract:With recent advances of in-depth gene sequencing technology and bioinformatics analysis, molecular genetic mechanisms and individual differences of malignant tumors have been further elucidated. With a literature review of high-risk neuroblastomas, molecular genetic features, chromosomal abnormalities, gene mutations, transcriptional regulations and epigenetic modifications were summarized. Also tumor layered diagnosis, targeted treatment and precise therapeutics were discussed.
Development of Differentiation Modulators and Targeted Agents for Treating Neuroblastoma.

Zegao Jin,Yang Lu,Yizhe Wu,Jinxin Che,Xiaowu Dong

DOI: https://doi.org/10.1016/j.ejmech.2020.112818

IF: 7.088

2020-01-01

European Journal of Medicinal Chemistry

Abstract:Neuroblastoma (NB) is one of the most common pediatric malignancies. Easy metastasis, poor prognosis, and a high degree of heterogeneity of NB hinder its successful treatment. Several different therapeutic strategies have been developed to overcome these problems, including differentiation and targeted therapy. In this review, we summarize the recent development of differentiation modulators and targeted agents for treating NB. Several promising targets of NB were also discussed.
Neuroblastoma and its Targets Therapies: A Medicinal Chemistry Review

Amgad Gerges,Una Canning

DOI: https://doi.org/10.1002/cmdc.202300535

IF: 3.54

2024-02-12

ChemMedChem

Abstract:Neuroblastoma (NB) is a childhood malignant tumour belonging to a group of embryonic tumours originating from progenitor cells of the sympathoadrenal lineage. The heterogeneity of NB is reflected in the survival rates of those with low and intermediate risk diseases who have survival rates ranging from 85 to 90 %. However, for those identified with high‐risk Stage 4 NB, the treatment options are much more limited. For this group, current treatment consists of immunotherapy (monoclonal antibodies) in combination with anti‐cancer drugs and has a 40 to 50 % survival rate. The purpose of this review is to summarise NB research from a medicinal chemistry perspective and to highlight advances in targeted drug therapy in the field. The review examines the medicinal chemistry of a number of drugs tested in research, some of which are currently under clinical trial. It concludes by proposing that future medicinal chemistry research into NB should consider other possible target therapies and adopt a multi‐target drug approach rather than a one‐drug‐one‐target approach for improved efficacy and less drug‐drug interaction for the treatment of NB Stage 4 (NBS4) patients.

pharmacology & pharmacy,chemistry, medicinal
Future Perspectives of Precision Medicine for NSCLC

Caicun Zhou,Fei Zhou

DOI: https://doi.org/10.1093/annonc/mdy357

IF: 51.769

2018-01-01

Annals of Oncology

Abstract:Over the past decade, significant advances have been made in the management of advanced NSCLC. The dramatic development of individualized therapies have propelled this malignance to the forefront of precision medicine. Nowadays, NSCLC has been divided into several distinct subtypes based on molecular alterations, including EGFR mutations, ALK/ROS1/NTRK translocations, and BRAFV600E mutations et al. Targeted therapy inhibiting specific actionable driver genes has resulting in a significant improvement in response rate and disease control. Targeted therapies for rare oncogenic drivers, including EGFR 20 insertions, HER2 exon 20 mutations, RET fusions, etc., are also under clinical development currently. Notably, due to low frequency of uncommon driver genes, classical randomized-controlled trial may not be the optimal approaches. Innovative biomarker-driven trials, such as Umbrella and Basket trials, may help screening patients effectively and evaluating multiple targeted drugs in matched patients. On the other hand, immune checkpoint blockades (ICBs) by inhibiting the programmed death protein 1/programmed death ligand 1 axis has yielded promising clinical responses in patients with advanced NSCLC, especially for those without EGFR/ALK aberrations. However, the response rate to ICBs is low (about 20%), mainly due to the dynamic expression of PD-L1 on tumor cells or immune cells, degree of mutational/neoantigen load, intratumoral heterogeneity, infiltrated immune cells of tumor microenvironment of NSCLC. Unlike targeted therapy, most single-gene biomarkers are not accurate for predicting ICBs efficacy and multi-omics and holistic approaches are needed. ICBs in combinations with chemotherapy, radiation therapy, or novel immunomodulatory agents are also currently being evaluated. However, the optimal order or duration of these drugs also needs further investigation. Nevertheless, there is still a lot of work to do before the era of precision medicine is truly coming.
Advances in Liquid Biopsy in Neuroblastoma

Zhenjian Zhuo,Lei Lin,Lei Miao,Meng Li,Jing He

DOI: https://doi.org/10.1016/j.fmre.2022.08.005

2022-01-01

Fundamental Research

Abstract:Even with intensive treatment of high-risk neuroblastoma (NB) patients, half of high-risk NB patients still relapse. New therapies targeting the biological characteristics of NB have important clinical value for the personalized treatment of NB. However, the current biological markers for NB are mainly analyzed by tissue biopsy. In recent years, circulating biomarkers of NB based on liquid biopsy have attracted more and more attention. This review summarizes the analytes and methods for liquid biopsy of NB. We focus on the application of liquid biopsy in the diagnosis, prognosis assessment, and monitoring of NB. Finally, we discuss the prospects and challenges of liquid biopsy in NB.
Research frontiers and reflections on neuroblastoma

Jiarui Pu,Qiangsong Tong

DOI: https://doi.org/10.12354/j.issn.1000-8179.2023.20221330

2023-01-01

Chinese Journal of Clinical Oncology

Abstract:Neuroblastoma is the most common intracranial solid tumor in children. It is often found at an advanced stage and is prone to metastasis. Even when high-risk patients receive high-intensity treatment, it can still recur or metastasize, and the prognosis is poor. Currently, the pathogenesis and treatment of neuroblastoma have become a research focus and are recognized as difficult issues in the study of pediatric solid tumors. In recent years, with the progress of single-cell sequencing and other techniques, many advances have been made in research on the pathogenesis and management of neuroblastoma. This article reviews the recent progress of research on neuroblastoma,including its origin and molecular, genetic, and immunological regulation mechanisms, and discusses the latest advances in research on monoclonal antibodies, tumor vaccines, adoptive cell therapy, and small-molecule inhibitors of neuroblastoma.
Pathogenesis, Biomarkers and Therapeutic Targets

Niels Vercouillie,Zhiyao Ren,Eva Terras,Tim Lammens

DOI: https://doi.org/10.3390/ijms25115690

IF: 5.6

2024-05-24

International Journal of Molecular Sciences

Abstract:Neuroblastoma is the most common malignant extracranial solid tumor of childhood. Recent studies involving the application of advanced high-throughput "omics" techniques have revealed numerous genomic alterations, including aberrant coding-gene transcript levels and dysfunctional pathways, that drive the onset, growth, progression, and treatment resistance of neuroblastoma. Research conducted in the past decade has shown that long non-coding RNAs, once thought to be transcriptomic noise, play key roles in cancer development. With the recent and continuing increase in the amount of evidence for the underlying roles of long non-coding RNAs in neuroblastoma, the potential clinical implications of these RNAs cannot be ignored. In this review, we discuss their biological mechanisms of action in the context of the central driving mechanisms of neuroblastoma, focusing on potential contributions to the diagnosis, prognosis, and treatment of this disease. We also aim to provide a clear, integrated picture of future research opportunities.

biochemistry & molecular biology,chemistry, multidisciplinary
Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics

Daniil Sokolov,Neha Sharda,Aindrila Banerjee,Kseniia Denisenko,Emad B Basalious,Hem Shukla,Jaylyn Waddell,Nadia M Hamdy,Aditi Banerjee

DOI: https://doi.org/10.2174/0113816128277350231219062154

Abstract:Background: Medulloblastomas (MDB) are malignant, aggressive brain tumors that primarily affect children. The survival rate for children under 14 is approximately 72%, while for ages 15 to 39, it is around 78%. A growing body of evidence suggests that dysregulation of signaling mechanisms and noncoding RNA epigenetics play a pivotal role in this disease. Methodology: This study conducted an electronic search of articles on websites like PubMed and Google. The current review also used an in silico databases search and bioinformatics analysis and an extensive comprehensive literature search for original research articles and review articles as well as retrieval of current and future medications in clinical trials. Results: This study indicates that several signaling pathways, such as sonic hedgehog, WNT/β-catenin, unfolded protein response mediated ER stress, notch, neurotrophins and TGF-β and ERK, MAPK, and ERK play a crucial role in the pathogenesis of MDB. Gene and ncRNA/protein are also involved as an axis long ncRNA to sponge micro-RNAs that affect downstream signal proteins expression and translation affection disease pathophysiology, prognosis and present potential target hit for drug repurposing. Current treatment options include surgery, radiation, and chemotherapy; unfortunately, the disease often relapses, and the survival rate is less than 5%. Therefore, there is a need to develop more effective treatments to combat recurrence and improve survival rates. Conclusion: This review describes various MDB disease hallmarks, including the signaling mechanisms involved in pathophysiology, related-causal genes, epigenetics, downstream genes/epigenes, and possibly the causal disease genes/non-protein coding (nc)RNA/protein axis. Additionally, the challenges associated with MDB treatment are discussed, along with how they are being addressed using nano-technology and nano-biomedicine, with a listing of possible treatment options and future potential treatment modalities.
Molecular Profiling-Based Precision Medicine In Cancer: A Review Of Current Evidence And Challenges

Qi Zhang,Qihan Fu,Xueli Bai,Tingbo Liang

DOI: https://doi.org/10.3389/fonc.2020.532403

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Matched therapy based on next-generation sequencing is now a part of routine care to guide the treatment of patients with advanced solid tumors. However, whether and to what extent patients can benefit from this strategy on a large scale remains uncertain. In the past decade, several clinical studies were performed in this field, among which only one was a randomized trial. We reviewed the literature on this topic and summarize the existing data about the efficacy of this treatment strategy. Currently, the evidence is promising but not solid. Multiple ongoing trials are also summarized. We also discuss the limitations of this treatment strategy and certain unsolved important problems, including how to select the sample and target level, how to interpret the results, and the problem of drug accessibility. All these issues should receive more attention in future clinical trial design and the application of target therapy in cancer treatment.
Current status of precision oncology in adult glioblastoma

Johannes Weller,Anna‐Laura Potthoff,Thomas Zeyen,Christina Schaub,Cathrina Duffy,Matthias Schneider,Ulrich Herrlinger

DOI: https://doi.org/10.1002/1878-0261.13678

2024-06-22

Molecular Oncology

Abstract:This review summarizes the current status of precision oncology – targeted therapies based on individual genetic profiles – in glioblastoma. Although some treatments show promise, their applicability and effectiveness remain limited, underlining the need for innovative approaches. Novel concepts to advance precision oncology and improve patient outcomes are discussed. The concept of precision oncology, the application of targeted drugs based on comprehensive molecular profiling, has revolutionized treatment strategies in oncology. This review summarizes the current status of precision oncology in glioblastoma (GBM), the most common and aggressive primary brain tumor in adults with a median survival below 2 years. Targeted treatments without prior target verification have consistently failed. Patients with BRAF V600E‐mutated GBM benefit from BRAF/MEK‐inhibition, whereas targeting EGFR alterations was unsuccessful due to poor tumor penetration, tumor cell heterogeneity, and pathway redundancies. Systematic screening for actionable molecular alterations resulted in low rates (

oncology
Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis

Mengliang Han,Fei Duan,Zhaolong Wang,Zhiguang Zhang,Hui Ren

DOI: https://doi.org/10.3389/fonc.2024.1383805

IF: 4.7

2024-10-11

Frontiers in Oncology

Abstract:Background: Neuroblastoma (NB), a prevalent extracranial solid tumor in children, stems from the neural crest. Omics technologies are extensively employed in NB, and We analyzed published articles on NB omics to understand the research trends and hot topics in NB omics. Method: We collected all articles related to NB omics published from 2005 to 2023 from the Web of Science Core Collection database. Subsequently, we conducted analyses using VOSviewer, CiteSpace, Bibliometrix, and the Bibliometric online analysis platform (https://bibliometric.com/ ). Results: We included a total of 514 articles in our analysis. The increasing number of publications in this field since 2020 indicates growing attention to NB omics, gradually entering a mature development stage. These articles span 50 countries and 1,000 institutions, involving 3,669 authors and 292 journals. The United States has the highest publication output and collaboration with other countries, with Germany being the most frequent collaborator. Capital Medical University and the German Cancer Research Center are the institutions with the highest publication count. The Journal of Proteome Research and the Journal of Biological Chemistry are the most prolific journal and most co-cited journal, respectively. Wang, W, and Maris, JM are the scholars with the highest publication count and co-citations in this field. "Neuroblastoma" and "Expression" are the most frequent keywords, while "classification," "Metabolism," "Cancer," and "Diagnosis" are recent key terms. The article titled "Neuroblastoma" by John M. Maris is the most cited reference in this analysis. Conclusion: The continuous growth in NB omics research underscores its increasing significance in the scientific community. Omics technologies have facilitated the identification of potential biomarkers, advancements in personalized medicine, and the development of novel therapeutic strategies. Despite these advancements, the field faces significant challenges, including tumor heterogeneity, data standardization issues, and the translation of research findings into clinical practice.

oncology
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification

Xiaoxiao Hu,Yilu Zhou,Charlotte Hill,Kai Chen,Cheng Cheng,Xiaowei Liu,Peiwen Duan,Yaoyao Gu,Yeming Wu,Rob M. Ewing,Zhongrong Li,Zhixiang Wu,Yihua Wang

DOI: https://doi.org/10.1038/s41416-024-02666-y

IF: 9.075

2024-03-30

British Journal of Cancer

Abstract:Despite the extensive study of MYCN -amplified neuroblastomas, there is a significant unmet clinical need in MYCN non-amplified cases. In particular, the extent of heterogeneity within the MYCN non-amplified population is unknown.

oncology
The Role of Liquid Biopsy in Neuroblastoma: A Scoping Review

Jitender Singh,Nitin J Peters,Pramod Avti,Amita Trehan,J K Mahajan,Prema Menon,Deepak Bansal,Ravi Prakash Kanojia

DOI: https://doi.org/10.1016/j.jpedsurg.2024.161887

2024-08-30

Abstract:Background: Neuroblastoma (NBL), is the most common, non-CNS solid tumor of childhood. This disease presents with unique biological and clinical challenges necessitating accurate diagnosis, prognosis assessment, treatment, and vigilant monitoring. Liquid biopsy is an upcoming, innovative, and non-invasive diagnostic modality. It has the potential to detect tumors and perform therapeutic monitoring through the analysis of circulating biomarkers in blood, urine, saliva, and other bodily fluids. Methodology: This scoping review offers an in-depth exploration, of the current landscape of liquid biopsy-based biomarkers in NBL. The review looks at the clinical implications, prevalent challenges, and future outlook of their clinical applications in NBL. The scoping review adhered to the guidelines of the PRISMA extension for scoping reviews, known as PRISMA-ScR, as the skeletal framework. The review involved comprehensive searches for liquid biopsy-based biomarkers in NBL across multiple databases, including PUBMED, EMBASE, SCOPUS, and WEB of Science, without restrictions. Results: The scoping review process uncovered a significant body of literature (n = 201) that underwent meticulous scrutiny, ultimately leading to the final selection of studies (n = 15). The liquid biopsy biomarkers included circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other entities in bodily fluids. Their evaluation focused on associations with clinical outcomes such as overall survival, event-free survival, and risk stratification in NBL. Conclusion: Our findings highlight the potential of liquid biopsy biomarkers to revolutionize NBL diagnosis and therapeutic monitoring. This rapidly evolving frontier in pediatric oncology suggests significant advancements in precision medicine for the management of NBL.
Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma

Lijuan Feng,Siqi Li,Chaoran Wang,Jigang Yang

DOI: https://doi.org/10.1053/j.semnuclmed.2022.12.004

Abstract:Neuroblastoma is the most common extracranial solid tumor in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from spontaneous regression or maturing to highly aggressive. About half of pediatric neuroblastoma patients develop the metastatic disease at diagnosis, which carries a poor prognosis. Nuclear medicine plays a pivotal role in the diagnosis, staging, response assessment, and long-term follow-up of neuroblastoma. And it has also played a prominent role in the treatment of neuroblastoma. Because the structure of metaiodobenzylguanidine (MIBG) is similar to that of norepinephrine, 90% of neuroblastomas are MIBG-avid. 123I-MIBG whole-body scintigraphy is the standard nuclear imaging technique for neuroblastoma, usually in combination with SPECT/CT. However, approximately 10% of neuroblastomas are MIBG nonavid. PET imaging has many technical advantages over SPECT imaging, such as higher spatial and temporal resolution, higher sensitivity, superior quantitative capability, and whole-body tomographic imaging. In recent years, various tracers have been used for imaging neuroblastoma with PET. The importance of patient-specific targeted radionuclide therapy for neuroblastoma therapy has also increased. 131I-MIBG therapy is part of the front-line treatment for children with high-risk neuroblastoma. And peptide receptor radionuclide therapy with radionuclide-labeled somatostatin analogues has been successfully used in the therapy of neuroblastoma. Moreover, radioimmunoimaging has important applications in the diagnosis of neuroblastoma, and radioimmunotherapy may provide a novel treatment modality against neuroblastoma. This review discusses the use of current and novel radiopharmaceuticals in nuclear medicine imaging and therapy of neuroblastoma.
Precision medicine in non-small cell lung cancer: Current applications and future directions

Soo-Ryum Yang,Helena Yu,Diana Mandelker,Marc Ladanyi,Reinhard Büttner,Anne M. Schultheis

DOI: https://doi.org/10.1016/j.semcancer.2020.07.009

IF: 17.012

2020-07-01

Seminars in Cancer Biology

Abstract:<p>Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there are highly effective targeted therapies against EGFR, ALK, ROS1, BRAF, TRK, RET, and MET. In addition, investigational therapies for KRAS, NRG1, and HER2 have shown promising results and may become standard-of-care in the near future. In parallel, immune-checkpoint therapy has emerged as an indispensable treatment modality, especially for patients lacking actionable oncogenic drivers. While PD-L1 expression has shown modest predictive utility, biomarkers for immune-checkpoint inhibition in NSCLC have remained elusive and represent an area of active investigation. Given the growing importance of biomarkers, optimal utilization of small tissue biopsies and alternative genotyping methods using circulating cell-free DNA have become increasingly integrated into clinical practice. In this review, we will summarize the current landscape and emerging trends in precision medicine for patients with advanced NSCLC with a special focus on predictive biomarker testing.</p>

oncology
Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

Atif A. Ahmed,Lei Zhang,Naresh Reddivalla,Maxine Hetherington

DOI: https://doi.org/10.1080/08880018.2017.1330375

2017-04-03

Pediatric Hematology and Oncology

Abstract:Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8-10% of all childhood malignancies. The tumor is characterized by a spectrum of histopathologic features and a heterogeneous clinical phenotype. Modern multimodality therapy results in variable clinical response ranging from cure in localized tumors to limited response in aggressive metastatic disease. Accurate clinical staging and risk assessment based on clinical, surgical, biologic and pathologic criteria are of pivotal importance in assigning prognosis and planning effective treatment approaches. Numerous studies have analyzed the presence of several clinicopathologic and biologic factors in association with the patient's prognosis and outcome. Although patient's age, tumor stage, histopathologic classification, and MYCN amplification are the most commonly validated prognostic markers, several new gene mutations have been identified in sporadic and familial neuroblastoma cases that show association with an adverse outcome. Novel molecular studies have also added data on chromosomal segmental aberrations in MYCN nonamplified tumors. In this review, we provide an updated summary of the clinical, serologic and genetic prognostic indicators in neuroblastoma including classic factors that have consistently played a role in risk stratification of patients as well as newly discovered biomarkers that may show a potential significance in patients' management.

oncology,pediatrics,hematology
Advances in Targeted Therapy for Cancer: Precision Medicine Approaches

,Beatrice Brenda Asha

DOI: https://doi.org/10.59298/idosrjas/2024/9.2.636700

2024-08-13

Abstract:Advances in targeted therapy and precision medicine have revolutionized cancer treatment by focusing on therapies that specifically address the molecular and genetic abnormalities driving tumor growth. This review explores the mechanisms underlying targeted therapies, including small molecule inhibitors, monoclonal antibodies, antibody-drug conjugates, and gene editing technologies. The integration of precision medicine, which tailors treatments based on detailed molecular profiling of tumors, has led to significant breakthroughs such as next-generation inhibitors, improved antibody-drug conjugates, and innovative RNA-based therapies. Despite these advances, challenges such as resistance mechanisms, adverse effects, and high costs remain. Future directions include the incorporation of artificial intelligence for drug discovery, expansion of precision oncology, and development of novel therapeutic modalities. A comprehensive literature review and expert consultation to synthesize current advancements and identify future research opportunities was utilised in writing this review article. This article aims to provide insights into how targeted therapy and precision medicine are transforming cancer treatment and outlines the path forward for achieving more effective and personalized cancer care. Keywords: Targeted Therapy, Precision Medicine, Genomic Profiling, Antibody-Drug Conjugates (ADCs), Artificial Intelligence.

Narrative review: precision medicine applications in neuroblastoma—current status and future prospects

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Precision Medicine in Pediatric Neurooncology: A Review

Recent advances in molecular genetic characterization of high-risk neuroblastoma

Development of Differentiation Modulators and Targeted Agents for Treating Neuroblastoma.

Neuroblastoma and its Targets Therapies: A Medicinal Chemistry Review

Future Perspectives of Precision Medicine for NSCLC

Advances in Liquid Biopsy in Neuroblastoma

Research frontiers and reflections on neuroblastoma

Pathogenesis, Biomarkers and Therapeutic Targets

Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics

Molecular Profiling-Based Precision Medicine In Cancer: A Review Of Current Evidence And Challenges

Current status of precision oncology in adult glioblastoma

Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification

The Role of Liquid Biopsy in Neuroblastoma: A Scoping Review

Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma

Precision medicine in non-small cell lung cancer: Current applications and future directions

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

Advances in Targeted Therapy for Cancer: Precision Medicine Approaches